MROH2B and preeclampsia: Given that sPIF finished first-in-human Phase Ib clinical trial (NCT02239562), sPIF therapy in pregnancy disorders such as preeclampsia, early pregnancy loss, and fetal loss can be envisioned [20,21,27].